The company’s products portfolio include Fibrillex, a phase III clinical trial completed product for the treatment of AA Amyloidosis; Alzhemed, a phase III clinical trial product for the treatment of Alzheimer's diseases; Cerebril, a phase IIa clinical trial completed product for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy; and NC-1461, which is in preclinical testing for the prevention of epileptic seizures.
Neurochem was incorporated in 1993 and is headquartered in Laval, Canada.
